China Cord Blood Stock News

HONG KONG , Dec. 17, 2021 /PRNewswire/ -- Global Cord Blood Corporation (NYSE: CO) ("GCBC" or the "Company"), China''s leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services, today announced that its Board of Directors (the "Board") decided to reject the non-binding proposal letter ("Alternate Ocean Proposal") from Alternate Ocean Investment Company Limited ("Alternate Ocean") received by the Board dated March 2, 2021 , pursuant to which Alternate Ocean proposed to acquire all outstanding ordinary shares of the Company for US$5.00 per ordinary share in cash, based on the recommendation from a special committee of independent directors (the "Special Committee"). The Special Committee and the Board believe such proposal in its original form fails to properly reflect the value of the Company and maximize shareholder value. About Global Cord Blood Corporation Global Cord Blood Corporation is the first and largest umbilical cord blood banking operator in China in terms of geographical coverage and the only cord blood banking operator with multiple licenses.

HONG KONG , Dec. 7, 2021 /PRNewswire/ -- Global Cord Blood Corporation (NYSE: CO) ("GCBC" or the "Company"), China''s leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing, and stem cell storage services, today announced the results of its 2021 Annual General Meeting of shareholders, held on December 7, 2021 , in Hong Kong S.A.R., China . At the Annual General Meeting, the Company''s shareholders ratified the re-appointment of KPMG Huazhen LLP as independent auditors of the Company for the financial year ending March 31, 2022 , and authorized any duly formed committee of the directors to fix the remuneration of the independent auditors; and re-elected Ms. Jennifer J. Weng , Mr. Ping Xu and Mr. Jacky Cheng as Class C directors of the Company until the Company''s 2024 annual general meeting, or until their respective successors are duly appointed and qualified. About Global Cord Blood Corporation Global Cord Blood Corporation is the first and largest umbilical cord blood banking operator in China in terms of geographical coverage and the only cord blood banking operator with multiple licenses.

Revenues increased 10% this quarter. The company grew in subscribers count this quarter and this was a positive sign.

Global Cord Blood Corporation (CO) Q2 2022 Results - Earnings Call Transcript

Global Cord Blood Corp (NYSE:CO) stock rose 5.99% (As on Nov 25, 7:59:04 AM UTC-4, Source: Google Finance) after the company in the second quarter The post Global Cord Blood Corp (NYSE:CO) reported 9.8% year-over-year increase in the total revenues appeared first on FXDailyReport.Com .

Global Cord Blood Corporation (NYSE:CO) shares, rose in value on Wednesday, 11/24/21, with the stock price up by 4.94% to the previous days close as strong demand from buyers drove the stock to $4.25. Actively observing the price movement in the last trading, the stock closed the session at $4.05, falling within a range of Global Cord Blood Corporation (NYSE: CO): Blank Check For Growth? Read More »

HONG KONG , Sept. 17, 2021 /PRNewswire/ -- Global Cord Blood Corporation (NYSE: CO) ("GCBC" or the "Company"), China's leading provider of cord blood collection, laboratory testing, hematopoietic stem

Global Cord Blood Corporation (CO) Q1 2022 Results - Earnings Call Transcript

1Q22 Added 19,673 New Subscribers Revenues Up 12.2% YoY to RMB315.2 Million ($48.8 Million) Gross Profit Up 12.6% YoY to RMB267.3 Million ($41.4 Million) Operating Income Up 17.3% YoY to RMB156.6 Mil

Global Cord Blood Is An Undervalued Business With Accelerating Growth, Benefiting From China's Policy Changes

HONG KONG, July 29, 2021 /PRNewswire/ -- Global Cord Blood Corporation (NYSE: CO) ("GCBC" or the "Company"), China's leading provider of cord blood collection, laboratory testing, hematopoietic stem

Global Cord Blood had a decent quarter, with subscriber growth improving both YoY and QoQ.

Global Cord Blood Corporation (CO) Management on Q4 2021 Results - Earnings Call Transcript